GlassScriptPhysician profile
Michelle D Price
NPI 1508279589
$3,125.26
in general payments reported to CMS, 2019-2025
15 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2022: $448 · 2023: $818 · 2024: $1,032 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.39 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $947.85 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $583.18 | 2023-2025 | Entyvio |
| Janssen Biotech, INC. | $512.39 | 2022-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $161.44 | 2024-2025 | |
| Celgene Corporation | $148.23 | 2022-2024 | Zeposia |
| Pfizer INC. | $144.19 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $138.76 | 2023-2024 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.98 | 2022-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $106.11 | 2024-2025 | Resmetirom, Rezdiffra |
| Genzyme Corporation | $68.02 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $43.35 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $43.12 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $41.02 | 2023-2024 | Ocaliva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.44 | 2023 | |
| Ardelyx, INC. | $23.18 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.